VBI Vaccines Inc. (Nasdaq: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that Jeff Baxter, President and CEO, will present at the JMP Securities Life Sciences Conference on Thursday, June 21, 2018, at...
Read More
Categories
VBI Vaccines Inc. (NASDAQ: VBIV) ("VBI" or the "Company"), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced the voting results from its annual general meeting of shareholders held on May 24, 2018 (the "Meeting"). The...
Read More
CMV neutralizing antibodies against fibroblast cell infection induced in 100% of subjects who received the highest dose Safe and well-tolerated at all doses with no safety signals observed Conference call and webcast today, Thursday, May 10, 2018, at 8:30 AM...
Read More
Enrollment completed in PROTECT Phase 3 clinical study of Sci-B-Vac® Hepatitis B Vaccine Key upcoming milestones in 2018 for lead eVLP vaccine candidates, VBI-1501 for prevention of Congenital Cytomegalovirus (CMV) and VBI-1901 for the treatment of glioblastoma (GBM) VBI Vaccines...
Read More
More than 1,600 subjects enrolled in PROTECT study Topline data expected mid-2019 VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”) today announced the completion of enrollment with the last patient receiving the first dose in the ongoing PROTECT Phase 3 study of...
Read More
Independent Data and Safety Monitoring Board (DSMB) unanimously recommends continuation of study without modification Low-dose study arm: enrollment complete Intermediate-dose study arm: enrollment commenced VBI Vaccines Inc. (Nasdaq: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology...
Read More
VBI Vaccines Inc. ("VBI" or the "Company") (Nasdaq: VBIV) (TSX:VBV), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that it has applied to voluntarily delist its common shares (the "Shares") from the Toronto Stock Exchange...
Read More
Sam Chawla, of Perceptive Advisors, to resign from VBI Board of Directors Tomer Kariv, Chairman and CEO of The Pontifax Group, to replace Ran Nussbaum on VBI’s Board of Directors VBI Vaccines Inc. (Nasdaq: VBIV) (TSX:VBV) (VBI), a commercial-stage biopharmaceutical...
Read More
Two-part Phase 1/2a study of VBI-1901 to enroll patients with recurrent GBM Part A: Dose escalation to enroll up to 18 patients Part B: Subsequent extension of optimal dose to enroll up to 10 additional patients VBI Vaccines Inc. (Nasdaq:VBIV)...
Read More
Patient dosing commenced on December 18, 2017 4,800 subjects across two Phase 3 studies: PROTECT and CONSTANT 15-month program - headline data expected Q2 2019 VBI Vaccines Inc. (Nasdaq: VBIV) (TSX: VBV) (“VBI”) announced today the initiation of the global...
Read More
Media Contact
Nicole Anderson, Communications Executive
Telephone: (617) 830-3031 x124
Email: ir@vbivaccines.com